AI Summary
✦ ClarthaStar Health is an Indian health insurer focused on retail health, group health, and personal accident and travel insurance. Retail policies for families, seniors, and pre-existing conditions are core revenue drivers, while group products serve employers and SMEs. Specialized offerings, including Star Women Care and Star Special Care, broaden coverage niches. Revenue grew 10.1% year-on-year, but recent analyst engagements provide limited evidence of a specific operational catalyst or margin expansion. Stable margins contrast with 13.8% profit decline, leaving ROE at a modest 7.5%. The earnings profile suggests underwriting or investment pressures may be limiting profit conversion despite continued top-line growth. At 50.3 times earnings, the shares appear overvalued relative to current growth and profitability. Positive investor sentiment may support the stock, but the key open question is whether earnings can accelerate without margin deterioration.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 23 analysts
Fundamentals
Fundamentals institutional score is 40 using EVA spread proxy -4.5%; accruals ratio -2.265; growth durability 98.1.
Valuation
Valuation institutional score is 70 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 55 using mean target upside 10.1%; dispersion penalty 20.5; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 59 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. valuation provide support, while fundamentals and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 13.4% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.06). Confidence: 86%.
Live forward EPS implies next-12-month EPS of ₹28.95. Applying the stock's normalized valuation corridor produces a fair range of ₹1,156.84 to ₹1,426.37, with base value near ₹1,305.36 (+123.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹28.95
Forward P/E
20.2x
Base Fair Value
₹1,305.36
Fair Range
₹1,156.84 - ₹1,426.37
Upside To Base
+123.3%
Estimate Source
Live forward EPS
Growth Estimate
+109.6%
5Y Average
3.54
Current
3.39
Overvalued
4.07
Undervalued
3.01
5Y Average
48.56
Current
51.11
Overvalued
49.27
Undervalued
39.96
5Y Average
1.77
Current
1.86
Overvalued
2.03
Undervalued
1.50
Peers & Comparison
Sector: Financials · Theme: Insurance
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
MAX FINANCIAL SERV LTD MFSLInsurance | -40.2% | 0.2% | 624.6x Premium | +402% vs avg | -5.7% |
ICICI LOMBARD GIC LIMITED ICICIGIInsurance | +10.9% | 8.8% | 34.0x Undervalued | -73% vs avg | -13.9% |
HDFC LIFE INS CO LTD HDFCLIFEInsurance | +15.2% | 1.9% | 58.7x Undervalued | -53% vs avg | -29.5% |
BSE LIMITED BSEStock Exchanges & Ratings | +64.0% | 48.9% | 50.4x Undervalued | -60% vs avg | +50.1% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 30.7x Undervalued | -75% vs avg | -5.0% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 65.1x Undervalued | -48% vs avg | +23.2% |
CG POWER AND IND SOL LTD CGPOWERHeavy Electrical Equipments | +14.0% | 9.8% | 111.4x Fair | -11% vs avg | +32.2% |
HERO MOTOCORP LIMITED HEROMOTOCOTwo Wheelers | +34.9% | 10.7% | 21.1x Undervalued | -83% vs avg | +26.2% |
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
MAX FINANCIAL SERV LTD MFSLInsurance | -40.2% | 0.2% | 624.6x Premium | +434% vs avg | -5.7% |
ICICI LOMBARD GIC LIMITED ICICIGIInsurance | +10.9% | 8.8% | 34.0x Undervalued | -71% vs avg | -13.9% |
HDFC LIFE INS CO LTD HDFCLIFEInsurance | +15.2% | 1.9% | 58.7x Undervalued | -50% vs avg | -29.5% |
GO DIGIT GENERAL INS LTD GODIGITInsurance | +8.6% | 4.8% | 49.9x Undervalued | -57% vs avg | -24.7% |
THE NEW INDIA ASSU CO LTD NIACLInsurance | +1.5% | 1.5% | 37.8x Undervalued | -68% vs avg | -2.8% |
ICICI PRU LIFE INS CO LTD ICICIPRULIInsurance | -83.1% | 2.6% | 43.3x Undervalued | -63% vs avg | -18.8% |
NIVA BUPA HEALTH INS CO L NIVABUPAInsurance | +80.0% | 4.8% | 80.6x Undervalued | -31% vs avg | +6.6% |
GENERAL INS CORP OF INDIA GICREInsurance | -1.3% | 18.3% | 6.5x Undervalued | -94% vs avg | -10.5% |
STAR HEALTH & AL INS CO L trades at a discount (51.1x vs peer avg 124.5x), suggesting potential undervaluation relative to the Insurance cohort. Peers include MAX FINANCIAL SERV LTD, ICICI LOMBARD GIC LIMITED, HDFC LIFE INS CO LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹5.29K CrJun 2026Latest net profit
₹550 CrJun 2026Latest EPS
₹9.34Jun 2026Net margin
14.3%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
Sales
₹5,285 Cr
Net Profit
₹550 Cr
EBITDA
₹755 Cr
EPS
₹9.34
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Sales | — | 4,081 | 4,693 | 4,567 | 4,648 | 5,285 |
| Expenses | — | 4,082 | 4,105 | 4,393 | 4,497 | 4,544 |
| Operating Profit | — | — | 602 | — | — | 755 |
| OPM % | — | — | 12.83% | — | — | 14.28% |
| Other Income | — | -0 | -230 | 0 | 0 | -275 |
| Interest | — | — | 14 | — | — | 13 |
| Profit before tax | — | -1 | 588 | 173 | 151 | 742 |
| Tax % | — | 158.62% | 25.49% | 26.06% | 26.37% | 25.88% |
| Net Profit | — | 1 | 438 | 128 | 111 | 550 |
| EPS in Rs | — | 0.01 | 7.45 | 2.18 | 1.89 | 9.34 |
All values in ₹ Crores unless otherwise stated. Source: Company filings.